Search Result

Results for "

Pioglitazone

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ferroptosis (7) Isotope-Labeled Compounds (4) PPAR (10)
By Research Areas:	Cancer (7) Metabolic Disease (10)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13956

*Pioglitazone* Maximum Cited Publications 25 Publications Verification U 72107	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-13956S

Pioglitazone-d4 U 72107-d₄	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].

HY-13956R

Pioglitazone (Standard)	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-13956S1

Pioglitazone-d4 (alkyl)	Isotope-Labeled Compounds PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

HY-14601R

Pioglitazone hydrochloride (Standard) U 72107A (Standard); AD 4833 (Standard)	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (hydrochloride) (Standard) is the analytical standard of Pioglitazone (hydrochloride). This product is intended for research and analytical applications. Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-13956B

Pioglitazone potassium U 72107 potassium	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .

HY-14601

Pioglitazone hydrochloride Maximum Cited Publications 25 Publications Verification U 72107A; AD 4833	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-144145S

Hydroxy Pioglitazone (M-II)-d4

Isotope-Labeled Compounds Others

Hydroxy Pioglitazone (M-II)-d₄ is the deuterium labeled Hydroxy Pioglitazone (M-II)[1].

*Hydroxy Pioglitazone* (M-II)-d4**	Isotope-Labeled Compounds	Others
Hydroxy Pioglitazone (M-II)-d₄ is the deuterium labeled Hydroxy Pioglitazone (M-II)[1].

HY-132379S

*Hydroxy Pioglitazone-d5 (M-IV) (Mixture of-diastereomers)*	Isotope-Labeled Compounds	Others
Hydroxy Pioglitazone-d₅ (M-IV) (Mixture of-diastereomers) is the deuterium labeled Hydroxy Pioglitazone (M-IV) (Mixture of-diastereomers)[1].

HY-117727A

Leriglitazone hydrochloride MIN-102 hydrochloride; HydroxyPioglitazone hydrochloride	PPAR	Metabolic Disease
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC₅₀ of 680 nM .

HY-117727

Leriglitazone MIN-102; HydroxyPioglitazone	PPAR	Metabolic Disease
Leriglitazone (MIN-102; Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K_i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC₅₀ of 680 nM .

HY-117727S

Leriglitazone-d4 MIN-102-d₄; HydroxyPioglitazone-d₄	Isotope-Labeled Compounds PPAR	Metabolic Disease
Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13956R

Pioglitazone (Standard)	Human Gut Microbiota Metabolites Source classification Endogenous metabolite	PPAR Ferroptosis
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

Cat. No.	Product Name	Chemical Structure

HY-13956S

Pioglitazone-d4
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].

HY-13956S1

Pioglitazone-d4 (alkyl)
Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

HY-144145S

Hydroxy Pioglitazone (M-II)-d4

Hydroxy Pioglitazone (M-II)-d₄ is the deuterium labeled Hydroxy Pioglitazone (M-II)[1].

*Hydroxy Pioglitazone* (M-II)-d4**
Hydroxy Pioglitazone (M-II)-d₄ is the deuterium labeled Hydroxy Pioglitazone (M-II)[1].

HY-132379S

*Hydroxy Pioglitazone-d5 (M-IV) (Mixture of-diastereomers)*
Hydroxy Pioglitazone-d₅ (M-IV) (Mixture of-diastereomers) is the deuterium labeled Hydroxy Pioglitazone (M-IV) (Mixture of-diastereomers)[1].

HY-117727S

Leriglitazone-d4
Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks